|
|
|
|
|
|
|
24.07.26 - 07:06
|
Almirall H1 2026 Results (Business Wire)
|
|
|
Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory
Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution.
The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth.
Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets.
The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM).
Almirall advances its innovation strategy through progress across its R&D pipeline, inclu...
|
|
|
|
|
|
|
|
|
|
|
11.05.26 - 07:21
|
Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business (Business Wire)
|
|
|
Almirall's European Dermatology business delivered solid growth of 19.3% YoY, reaching €166.3 MM in Q1 2026, driven by strong momentum across key growth drivers. This contributed to overall Net Sales of €291 MM, up 2.2% YoY and reflecting 9% growth on a Last-Twelve-Months (LTM) basis.
Performance continues to be driven by the biologics portfolio, with Ilumetri® showing 11.8% increase in sales vs Q1 2025 (total of €61.6 MM), and Ebglyss® delivering €41.9 MM quarterly sales – more than 2x YoY – boosted by sustained growth in recent launch countries.
Strong performance of the broad dermatology product portfolio in line with expectations – products driving relevance of Almirall in medical dermatology, including Wynzora® (20.8%, total of €9.3 MM) and Klisyri® (7.2%, total of €7.4 MM).
Total EBITDA was €67.5 MM, corresponding to 23.2% over Net Sales – improvement versus FY 2025 (21%).
Continued R&D pipeline progress includes the start of phase I of anti-IL-13/OX40L bispecific antibody...
|
|
|
|
|
04.05.26 - 09:45
|
Evotec: Schneller als gedacht – Aktie zieht deutlich an (Der Aktionaer)
|
|
|
Evotec meldet Fortschritte in der Dermatologie-Partnerschaft mit Almirall. Aus der gemeinsamen, auf mehrere Zielstrukturen ausgerichteten Wirkstoffsuche wurde ein präklinischer Entwicklungskandidat ausgewählt. Ziel sind neue Therapieoptionen für immunvermittelte entzündliche Hauterkrankungen mit hohem medizinischem Bedarf....
|
|
|
|
|
|
|
04.05.26 - 07:33
|
Corporate News: Evotec SE (EQS)
|
|
|
Evotec gibt ersten präklinischen Entwicklungskandidaten aus Dermatologie-Kooperation mit Almirall bekannt...
|
|
|
|
|
|
|
|
|
|
|
23.02.26 - 07:09
|
Almirall′s 2025 Results (Business Wire)
|
|
|
Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe
Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.
This revenue growth further advances Almirall's leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).
The continued strong performance of the biologics portfolio is the backbone of Almirall's growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
